References
- Ambrusa R, Kocbek P, Kristl J. (2009). Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm 381:153–9
- Du B, Li XT, Zhao Y, et al (2010). Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders. Pharmazie 65:471–6
- Eerdenbrugh VB, Mooter VG, Augustijns P. (2008). Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 364:64–75
- Fakes MG, Blisse JV, Feng Q, Sridhar D. (2009). Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm 370:167–74
- Ganta S, Paxton JW, Baguley BC, Garg S. (2009). Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm 367:179–86
- Geinsen K. (1988). Special pharmacology of the new sulfonylurea glimepiride. Drug Res 38:1120–30
- Jacobs C, Müller RH. (2002). Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 19:189–94
- Kaushal AM, Gupta P, Bansal AK. (2004). Amorphous drug delivery systems: molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst 21:133–93
- Keck CM, Müller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62:3–16
- Kesisoglou F. (2007). Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv. Drug Dev Rev 59:631–44
- Kipp J. (2004). The role of solid nanoparticle technology in the parenteral delivery of poor water-soluble drugs. Int J Pharm 284:109–22
- Kouichi I, Masaki W, Youhei N, et al (2005). Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diab Res Clin Prac 68:250–7
- Lipinski C. (2002). Poor aqueous solubility – an industry wide problem in drug discovery. Am Pharm Rev 5:82–5
- Massimo MB. (2003). Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 25:799–816
- Mauludin R, Müller RH, Kecket CM. (2009). Development of an oral rutin nanocrystal formulation. Int J Pharm 370:202–9
- Moschwitzer J, Achleitner G, Pomper H, Müller RH. (2004). Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 58:615–19
- Patravale VB, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 56:827–40
- Pu XH, Sun J, Wang Y, Wang YJ. (2009). Development of a chemically stable 10-hydroxycamptothecin nanosuspensions. Int J Pharm 379:167–73
- Quan P, Xia D, Piao HZ, et al (2011). Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation. AAPS PharmSciTech 12:1136–43
- Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785–96
- Rosario P, Claudio B, Piera F, et al (2002). Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16:53–61
- Shelesh J, Swarnlata S. (2010). Type 2 diabetes mellitus – its global prevalence and therapeutic strategies. Diab Metab Syndr 4:48–56
- Xia D, Quan P, Piao H, et al (2010). Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci 40:325–34
- Yang W, Keith P, Johnston KP, et al (2010). Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm 75:33–41
- Zhang DR, Tan TW, Gao L, et al (2007). Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm 33:569–75